
Altera™ combines Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) to enable deeper understanding of each cancer’s unique genomic signature. It identifies clinically relevant biomarkers that support the selection of targeted therapies and immunotherapies, while also helping match patients to appropriate clinical trials.
Altera™ is performed at Natera’s Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in the United States.
Technical Features
Technical Specifications
Feature | Details |
Method | WES (DNA) + WTS (RNA) + IHC |
Coverage | ~20,000 Genes, MSI, TMB, PD-L1 (22C3), HER2, Fusions, and Drug Sensitivity |
Sample Type | FFPE Tumor Tissue + EDTA Blood |
Clinical Utility | Targeted therapy selection Immunotherapy eligibility Clinical trial matching |
Turnaround Time | 3 Weeks |
While Altera™ determines the optimal treatment strategy, Signatera™ enables molecular recurrence monitoring. This dual approach ensures tissue conservation by utilizing a single tumor sample. It optimizes the therapeutic process and provides the opportunity for long-term personalized monitoring.
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, 34394 Şişli / Istanbul, Turkey
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00